{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:23:21Z","timestamp":1794774201058,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7717","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2018,8,9]]},"DOI":"10.1038\/s41586-018-0356-z","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T23:07:16Z","timestamp":1532473636000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis"],"prefix":"10.1038","volume":"560","author":[{"given":"Susan","family":"Wyllie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrinia","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"De Rycker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gresham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Urbaniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laste","family":"Stojanovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R. C.","family":"Simeons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Manthri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna M.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zuccotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Homeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Pflaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Boesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha","family":"Sastry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Berriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Ghidelli-Disse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Fiandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A. J.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Fairlamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"356_CR1","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","volume":"7","author":"J Alvar","year":"2012","unstructured":"Alvar, J. et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE\u00a07, e35671 (2012).","journal-title":"PLoS One"},{"key":"356_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0035-9203(03)80047-0","volume":"97","author":"K Ritmeijer","year":"2003","unstructured":"Ritmeijer, K. & Davidson, R. N. Royal Society of Tropical Medicine and Hygiene joint meeting with M\u00e9decins Sans Fronti\u00e8res at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. M\u00e9decins Sans Fronti\u00e8res interventions against kala-azar in the Sudan, 1989\u20132003. Trans. R. Soc. Trop. Med. Hyg. 97, 609\u2013613 (2003).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"356_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/cid\/cis474","volume":"55","author":"S Sundar","year":"2012","unstructured":"Sundar, S. et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 55, 543\u2013550 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"356_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/14728210903153862","volume":"14","author":"ML den Boer","year":"2009","unstructured":"den Boer, M. L., Alvar, J., Davidson, R. N., Ritmeijer, K. & Balasegaram, M. Developments in the treatment of visceral leishmaniasis. Expert Opin. Emerg. Drugs 14, 395\u2013410 (2009).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"356_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","volume":"101","author":"M Mueller","year":"2007","unstructured":"Mueller, M. et al. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg. 101, 19\u201324 (2007).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"356_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","volume":"537","author":"S Khare","year":"2016","unstructured":"Khare, S. et al. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 537, 229\u2013233 (2016).","journal-title":"Nature"},{"key":"356_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1017\/S003118201300142X","volume":"141","author":"R Don","year":"2014","unstructured":"Don, R. & Ioset, J.-R. Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141, 140\u2013146 (2014).","journal-title":"Parasitology"},{"key":"356_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/cmdc.201300072","volume":"8","author":"A Woodland","year":"2013","unstructured":"Woodland, A. et al. From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem 8, 1127\u20131137 (2013).","journal-title":"ChemMedChem"},{"key":"356_CR9","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1128\/AAC.02398-12","volume":"57","author":"M De Rycker","year":"2013","unstructured":"De Rycker, M. et al. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob. Agents Chemother. 57, 2913\u20132922 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"356_CR10","doi-asserted-by":"publisher","first-page":"e0004094","DOI":"10.1371\/journal.pntd.0004094","volume":"9","author":"A N\u00fchs","year":"2015","unstructured":"N\u00fchs, A. et al. Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity. PLoS Negl. Trop. Dis. 9, e0004094 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"356_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.toxlet.2005.10.016","volume":"162","author":"CJ Henderson","year":"2006","unstructured":"Henderson, C. J., Pass, G. J. & Wolf, C. R. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol. Lett. 162, 111\u2013117 (2006).","journal-title":"Toxicol. Lett."},{"key":"356_CR12","unstructured":"Miles, T. J. & Thomas, M. G. Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis. WIPO patent WO\/2016\/116563 (2016)."},{"key":"356_CR13","unstructured":"Ding, Q., Jiang, N. & Roberts, J. L. Pyrazolo pyrimidines. WIPO patent WO\/2005\/121107 (2005)."},{"key":"356_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035\u20131044 (2007).","journal-title":"Nat. Biotechnol."},{"key":"356_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd2410","volume":"6","author":"GC Terstappen","year":"2007","unstructured":"Terstappen, G. C., Schl\u00fcpen, C., Raggiaschi, R. & Gaviraghi, G. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6, 891\u2013903 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"356_CR16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1039\/c2mb25502b","volume":"9","author":"J Park","year":"2013","unstructured":"Park, J., Koh, M. & Park, S. B. From noncovalent to covalent bonds: a paradigm shift in target protein identification. Mol. Biosyst. 9, 544\u2013550 (2013).","journal-title":"Mol. Biosyst."},{"key":"356_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s12272-016-0791-z","volume":"39","author":"H Lee","year":"2016","unstructured":"Lee, H. & Lee, J. W. Target identification for biologically active small molecules using chemical biology approaches. Arch. Pharm. Res. 39, 1193\u20131201 (2016).","journal-title":"Arch. Pharm. Res."},{"key":"356_CR18","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1016\/j.bmcl.2015.06.023","volume":"25","author":"A Ursu","year":"2015","unstructured":"Ursu, A. & Waldmann, H. Hide and seek: identification and confirmation of small molecule protein targets. Bioorg. Med. Chem. Lett. 25, 3079\u20133086 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"356_CR19","doi-asserted-by":"publisher","first-page":"e36619","DOI":"10.1371\/journal.pone.0036619","volume":"7","author":"MD Urbaniak","year":"2012","unstructured":"Urbaniak, M. D., Guther, M. L. S. & Ferguson, M. A. J. Comparative SILAC proteomic analysis of Trypanosoma brucei bloodstream and procyclic lifecycle stages. PLoS ONE\u00a07, e36619 (2012).","journal-title":"PLoS One"},{"key":"356_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio799","volume":"2","author":"Y Liu","year":"2006","unstructured":"Liu, Y. & Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358\u2013364 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"356_CR21","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1016\/j.bmcl.2011.06.129","volume":"21","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I). Bioorg. Med. Chem. Lett. 21, 5633\u20135637 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"356_CR22","unstructured":"Freyne, E. J. E. et al. Pyrazolopyrimidines as cell cycle kinase inhibitors. WIPO patent WO\/2006\/074984 (2006)."},{"key":"356_CR23","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1101\/gr.122945.111","volume":"21","author":"MB Rogers","year":"2011","unstructured":"Rogers, M. B. et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 21, 2129\u20132142 (2011).","journal-title":"Genome Res."},{"key":"356_CR24","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1101\/gr.123430.111","volume":"21","author":"T Downing","year":"2011","unstructured":"Downing, T. et al. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 21, 2143\u20132156 (2011).","journal-title":"Genome Res."},{"key":"356_CR25","doi-asserted-by":"publisher","first-page":"e67327","DOI":"10.1371\/journal.pone.0067327","volume":"8","author":"S Monnerat","year":"2013","unstructured":"Monnerat, S. et al. Identification and functional characterisation of CRK12:CYC9, a novel cyclin-dependent kinase (CDK)\u2013cyclin complex in Trypanosoma brucei. PLoS ONE\u00a08, e67327 (2013).","journal-title":"PLoS One"},{"key":"356_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0166-6851(01)00220-1","volume":"113","author":"P Hassan","year":"2001","unstructured":"Hassan, P., Fergusson, D., Grant, K. M. & Mottram, J. C. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol. Biochem. Parasitol. 113, 189\u2013198 (2001).","journal-title":"Mol. Biochem. Parasitol."},{"key":"356_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1128\/EC.4.4.755-764.2005","volume":"4","author":"X Tu","year":"2005","unstructured":"Tu, X. & Wang, C. C. Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1\/S and G2\/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism. Eukaryot. Cell 4, 755\u2013764 (2005).","journal-title":"Eukaryot. Cell"},{"key":"356_CR28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/pr5012608","volume":"14","author":"G M\u00e9dard","year":"2015","unstructured":"M\u00e9dard, G. et al. Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 14, 1574\u20131586 (2015).","journal-title":"J. Proteome Res."},{"key":"356_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nchembio.957","volume":"8","author":"G Bergamini","year":"2012","unstructured":"Bergamini, G. et al. A selective inhibitor reveals PI3K\u03b3 dependence of TH17 cell differentiation. Nat. Chem. Biol. 8, 576\u2013582 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"356_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nbt.1759","volume":"29","author":"M Bantscheff","year":"2011","unstructured":"Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255\u2013265 (2011).","journal-title":"Nat. Biotechnol."},{"key":"356_CR31","first-page":"119","volume":"30","author":"DJ Bradley","year":"1977","unstructured":"Bradley, D. J. & Kirkley, J. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30, 119\u2013129 (1977).","journal-title":"Clin. Exp. Immunol."},{"key":"356_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/jac\/38.6.1041","volume":"38","author":"SL Croft","year":"1996","unstructured":"Croft, S. L., Snowdon, D. & Yardley, V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38, 1041\u20131047 (1996).","journal-title":"J. Antimicrob. Chemother."},{"key":"356_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1128\/AAC.50.1.73-79.2006","volume":"50","author":"K Seifert","year":"2006","unstructured":"Seifert, K. & Croft, S. L. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50, 73\u201379 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"356_CR34","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1128\/AAC.45.6.1872-1875.2001","volume":"45","author":"P Escobar","year":"2001","unstructured":"Escobar, P., Yardley, V. & Croft, S. L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45, 1872\u20131875 (2001).","journal-title":"Antimicrob. Agents Chemother."}],"updated-by":[{"DOI":"10.1038\/s41586-023-06364-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0356-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0356-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:08:35Z","timestamp":1688486915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-018-0356-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":34,"journal-issue":{"issue":"7717","published-print":{"date-parts":[[2018,8,9]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1038\/s41586-018-0356-z","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41586-023-06364-2","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]},"assertion":[{"value":"9 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-023-06364-2","URL":"https:\/\/doi.org\/10.1038\/s41586-023-06364-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These authors have shares in GlaxoSmithKline: P.G.W., S.D., T.J.M., K.D.R., S.C., R.L., S.G., M.Bo., H.P., P.C., G.D., D.G., S.G.-D. and J.M.F. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}